Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin and Pioglitazone Initial Combination Therapy in T2DM
NCT00397631Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Dec 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00397631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397631.